1-3 of 3
Sam Yuen
Close
Sort by
Journal Articles

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Clinical Trials & Observations
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1488–1495.
https://doi.org/10.1182/bloodadvances.2022008344
Published: 2023
Includes: Supplemental data
Journal Articles

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

Anas Younes, John M. Burke, Catherine Diefenbach, Silvia Ferrari, Cyrus Khan, Jeff P. Sharman, Monica Tani, Chaitra Ujjani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Michael Gilbertson
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5659–5667.
https://doi.org/10.1182/bloodadvances.2021006131
Published: 2022
Includes: Supplemental data
Journal Articles

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Clinical Trials & Observations
Kerry J. Savage, Steven M. Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Kensei Tobinai, Andrei Shustov, Marek Trneny, Sam Yuen, Pier Luigi Zinzani, Lorenz Trümper, Tim Ilidge, Owen A. O’Connor, Barbara Pro, Harry Miao, Veronica Bunn, Keenan Fenton, Michelle Fanale, Markus Puhlmann, Swaminathan Iyer
Journal: Blood Advances
Blood Adv (2022) 6 (19): 5550–5555.
https://doi.org/10.1182/bloodadvances.2020003971
Published: 2022
Includes: Supplemental data